BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery
Reuters
Yesterday
BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery
** Shares of drug developer Polyrizon PLRZ.O rise 12.6% to $14.00 premarket
** Co says it will develop an intranasal version of Clearmind’s CMND.O experimental MEAI therapy, being studied for addiction-related brain disorders
** CNMD's shares were up 20% at $1.7 premarket
** CNMD's MEAI is designed to reshape neural pathways without hallucinations; intranasal delivery may help faster absorption and bypass the liver, per co
** Co says its gel-like nasal platform aims to keep drugs longer in the nose and improve targeted delivery
** PLRZ shares down over 99%, CNMD down ~41% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.